Intelligent Investor

Nanosonics: Interim result 2017

Strong Trophon sales shows the way to a recurring future for this medical device world leader.
By · 20 Feb 2017
By ·
20 Feb 2017 · 3 min read
Upsell Banner

Recommendation

Nanosonics Limited - NAN
Current price
$2.70 at 16:40 (19 April 2024)

Price at review
$2.82 at (20 February 2017)

Max Portfolio Weighting
2%

Business Risk
Very high

Share Price Risk
Very high
All Prices are in AUD ($)

The first half of the 2017 financial year was another cracker for Nanosonics. Sales were up 132% to $36m for the six months to December, while the company made its first operating profit of $10.3m. Free cash flow was a healthy $8.2m, up 19% on the prior half. The result depicts a growth company in the early stages of a long-term roll out.

With the result already foreshadowed in Nanosonics posts strong sales, let's instead recap the company's strategy, which is like the razor/razor blade model pioneered by Gillette.

The first step in this approach is to establish a large installed base of razors (or Trophon units in Nanosonics' case), which locks the customer into ongoing purchases of consumables.

Nanosonics is doing exactly that with great success. Its installed base increased by 60% over the year to reach 12,300 units. North America has been the first target with 87% of the current installed base, but now the company is increasingly focusing abroad. Next on the hit list is the UK, Germany, and France, followed by Japan and the Middle East. In these new markets, Nanosonics is in various stages of building awareness and establishing its sales channels, which will form the basis of its medium-term growth aspirations.

Trophon units are a decent outlay for the medical department, costing around USD$13,000 depending on the sales channel. Nanosonics currently derives around two-thirds of its revenue from these one-off sales, a high yet normal proportion for a company early in a roll out.

As the installed base grows, we expect the proportion of sales from consumables to increase. This provides greater levels of recurring revenue. But with global adoption still in its infancy, it will be a slow road.

Nanosonics continues to trade at lofty multiples, but that might be justified given its potential for growth. We continue to recommend you take profits if and as the share price rises to a keep a maximum portfolio weighting of 2%. HOLD.

Note: The Intelligent Investor Growth Portfolio owns shares in Nanosonics. You can find out about investing directly in Intelligent Investor and InvestSMART portfolios by clicking here.

IMPORTANT: Intelligent Investor is published by InvestSMART Financial Services Pty Limited AFSL 226435 (Licensee). Information is general financial product advice. You should consider your own personal objectives, financial situation and needs before making any investment decision and review the Product Disclosure Statement. InvestSMART Funds Management Limited (RE) is the responsible entity of various managed investment schemes and is a related party of the Licensee. The RE may own, buy or sell the shares suggested in this article simultaneous with, or following the release of this article. Any such transaction could affect the price of the share. All indications of performance returns are historical and cannot be relied upon as an indicator for future performance.
Share this article and show your support

Join the Conversation...

There are comments posted so far.

If you'd like to join this conversation, please login or sign up here